Europe Pharmaceutical Water Market By Type of Pharmaceutical Water (Water for Injection, Purified Water, Highly Purified Water, Sterile Water for Injection, Irrigation, and Inhalation, Other); By Treatment Technology (Reverse Osmosis, Ultraviolet Disinfection, Distillation, Deionization, Others); By Application (Pharmaceutical & Biotechnology Manufacturing, Research Laboratories & Academic Institutes, Contract Manufacturing Organizations, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
The Europe Pharmaceutical Water Market was valued at USD 4,290.41 million in 2018, grew to USD 7,235.40 million in 2024, and is anticipated to reach USD 14,105.75 million by 2032, expanding at a CAGR of 8.0% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Europe Pharmaceutical Water Market Size 2024
USD 7,235.40 Million
Europe Pharmaceutical Water Market, CAGR
8.0%
Europe Pharmaceutical Water Market Size 2032
USD 14,105.75 Million
The Europe Pharmaceutical Water Market features strong competition among leading players such as Ecolab Inc., Veolia Water Technologies, Thermo Fisher Scientific Inc., Danaher Corporation, B. Braun Medical Inc., Merck KGaA, SteriCare Solutions, Baldwin Technology Company, Sigma-Aldrich (Merck KGaA), and Corning Incorporated. These companies dominate through advanced purification technologies, GMP-compliant water systems, and continuous innovation in automation and digital monitoring. They focus on sustainability, energy efficiency, and real-time validation to meet strict EMA and GMP standards. The United Kingdom emerged as the leading regional market in 2024, capturing a 24% share, supported by a strong pharmaceutical manufacturing base, advanced biopharmaceutical production, and ongoing investments in high-purity water infrastructure.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Europe Pharmaceutical Water Market grew from USD 4,290.41 million in 2018 to USD 7,235.40 million in 2024, and will reach USD 14,105.75 million by 2032, growing at 0% CAGR.
Water for Injection (WFI) led the market with a 42% share in 2024, driven by strict EMA standards, sterile drug production, and expanding biopharmaceutical manufacturing across the region.
Reverse Osmosis (RO) technology dominated with a 39% share, supported by efficiency, regulatory compliance, and widespread adoption for high-purity and WFI water generation.
Pharmaceutical & Biotechnology Manufacturing remained the largest application segment with a 58% share, propelled by biologics expansion, sterile injectable production, and advanced GMP-compliant facilities.
The United Kingdom led the regional market with a 24% share, followed by Germany (21%) and France (17%), supported by strong pharmaceutical infrastructure, regulatory compliance, and continuous investments in water purification systems.
Market Segment Insights
By Type of Pharmaceutical Water
Water for Injection (WFI) dominated the Europe Pharmaceutical Water Market in 2024 with a 42% share. Its leadership stems from strict regulatory demands for parenteral drug production and biopharmaceutical formulations. WFI systems ensure the highest purity level, meeting EMA and GMP standards. Rising investments in sterile manufacturing, vaccine development, and biologics production further boost adoption. Purified and highly purified water also show steady demand across formulation and cleaning processes in pharmaceutical facilities.
By Treatment Technology
Reverse Osmosis (RO) led the market in 2024 with a 39% share, supported by its efficiency, cost-effectiveness, and compliance with European Pharmacopeia standards. RO systems are widely used for removing dissolved impurities and achieving high-purity levels essential for both purified and WFI production. Continuous advancements in membrane technology, automation, and validation systems drive their adoption. Ultraviolet (UV) disinfection and distillation technologies also play key roles in microbial control and sterile water generation.
For instance, Merck KGaA upgraded its Milli-Q IQ 7003/7005 systems with advanced RO pre-treatment modules to enhance production of ultrapure water for life science applications.
By Application
Pharmaceutical & Biotechnology Manufacturing accounted for the largest market share of 58% in 2024. The segment benefits from increased biologics production, sterile injectable manufacturing, and stringent EU GMP water quality requirements. Continuous expansion of drug formulation plants and biologics R&D facilities sustains demand for high-purity water systems. Research laboratories, academic institutes, and contract manufacturing organizations (CMOs) also contribute significantly through their growing reliance on validated water systems for experimental and outsourced pharmaceutical operations.
For instance, Thermo Fisher Scientific expanded its biologics development facility in St. Louis , incorporating high-purity water processing units to enhance sterile injectable production.
Key Growth Drivers
Rising Biopharmaceutical Production and Sterile Drug Manufacturing
Europe’s growing focus on biopharmaceuticals and sterile injectables is a major growth driver. Increasing demand for vaccines, biosimilars, and biologic therapies has elevated the need for high-purity water systems. Pharmaceutical companies are investing heavily in advanced WFI and purified water units to meet stringent EMA and GMP quality standards. The expanding biopharma infrastructure across Germany, France, and the UK further supports installation of automated water purification technologies that ensure contamination-free operations and process reliability.
For instance, Veolia Water Technologies’ Orion™ system is widely adopted across Europe, integrating reverse osmosis and continuous electrodeionization to produce purified water meeting stringent USP and European Pharmacopoeia standards, while supporting energy reduction by up to 50%.
Stringent Regulatory Compliance and Quality Standards
The market benefits from Europe’s strict regulatory framework for water used in drug manufacturing. Agencies such as EMA and national GMP authorities mandate precise quality levels for purified and injectable water. These rules drive pharmaceutical companies to adopt advanced purification, monitoring, and validation systems. Compliance requirements for microbiological and chemical limits have prompted large-scale investments in automated and validated water treatment infrastructure across both established and emerging pharmaceutical hubs in the region.
For instance, Sartorius AG introduced an enhanced water filtration validation module designed to help European pharmaceutical manufacturers meet EMA and EU GMP Annex 1 sterility requirements.
Increasing Investments in Pharmaceutical Infrastructure
Rising capital expenditure in pharmaceutical and biotechnology facilities fuels market expansion. Ongoing projects focused on capacity expansion, modernization, and automation of production plants increase the need for reliable pharmaceutical water systems. Growing investments in contract manufacturing and R&D laboratories across the UK, France, and Italy enhance demand for customized purification setups. This infrastructure development supports higher output efficiency, improved regulatory compliance, and consistent quality in water-dependent manufacturing processes across the region.
Key Trends & Opportunities
Integration of Automation and Digital Monitoring Systems
Automation and digital water management are emerging as key trends in the market. Smart sensors, IoT-enabled monitoring, and AI-based control systems enhance process accuracy and reduce human intervention. These technologies improve traceability, energy efficiency, and predictive maintenance, helping facilities maintain compliance with GMP and European Pharmacopeia standards. Vendors focusing on digital integration gain a strong competitive edge by offering real-time performance tracking and remote monitoring solutions for pharmaceutical water operations.
For instance, Netafim, a global leader in irrigation solutions, uses IoT-enabled smart irrigation systems with sensors that adjust watering schedules based on real-time soil moisture and weather data, effectively enhancing water efficiency and crop yields.
Growing Shift Toward Sustainable Water Treatment Solutions
Sustainability-focused innovation presents a major opportunity for market growth. Manufacturers increasingly adopt energy-efficient RO systems, waste reduction units, and water recovery technologies to align with Europe’s environmental goals. Green manufacturing initiatives across the pharmaceutical sector encourage investment in low-energy distillation and hybrid purification methods. Companies emphasizing resource optimization and eco-friendly purification gain favor among regulatory bodies and end users seeking reduced operational costs and environmental footprints.
For instance, Aquature, another UK-based company, offers a green hydrogen-powered bio-electric refinery that converts wastewater chemical energy into green hydrogen with over 85% conversion efficiency, integrating AI and IoT for remote monitoring.
Key Challenges
High Capital and Operational Costs
Implementing pharmaceutical-grade water systems requires substantial initial investment and maintenance expenses. Costs related to installation, validation, and periodic compliance audits limit adoption among small and mid-sized manufacturers. Energy-intensive processes such as distillation and multi-stage purification further add to operational costs. The need for continuous system upgrades to meet evolving GMP standards adds financial pressure, posing a challenge for organizations with limited technical or capital resources.
Complexity in Compliance and Validation Processes
Adhering to Europe’s stringent water quality standards is technically challenging. Pharmaceutical companies must ensure full compliance with EU GMP, EMA, and European Pharmacopeia guidelines. Each production stage demands validated documentation, continuous monitoring, and periodic system requalification. This complexity often delays plant commissioning and increases regulatory costs. Smaller players lacking in-house validation expertise face difficulties maintaining consistent compliance across multi-country operations.
Limited Skilled Workforce and Technical Expertise
The shortage of skilled technicians capable of managing and validating complex purification systems poses a major challenge. Advanced pharmaceutical water systems require expertise in automation, validation, and regulatory documentation. Many facilities rely on external service providers, increasing dependency and operational risks. The talent gap slows system optimization and technology adoption, especially among mid-tier pharmaceutical companies striving to modernize production and meet strict European regulatory expectations.
Regional Analysis
United Kingdom
The United Kingdom led the Europe Pharmaceutical Water Market in 2024 with a 24% share. Strong pharmaceutical manufacturing, biopharmaceutical research, and a well-established regulatory framework support market expansion. The country’s emphasis on sterile injectable production and biologics increases demand for Water for Injection (WFI) and purified water systems. Investments in GMP-compliant infrastructure and automation strengthen operational reliability. Leading players continue to upgrade purification technologies to meet MHRA and EMA requirements. Continuous growth in contract manufacturing and R&D centers sustains long-term demand.
Germany
Germany captured a 21% share in 2024, driven by its strong pharmaceutical base and technological innovation. It remains a hub for pharmaceutical engineering and process automation, ensuring high-quality water purification systems. The presence of global pharmaceutical manufacturers encourages adoption of advanced RO and distillation systems. High regulatory standards and strict quality audits promote consistent upgrades to validated water systems. Continuous funding for research and cleanroom expansion boosts demand for high-purity water applications.
France
France accounted for a 17% share in 2024, supported by a growing biologics and vaccine manufacturing sector. Pharmaceutical companies continue investing in sustainable and energy-efficient water purification units. It benefits from well-structured regulatory oversight and widespread use of automated control systems in sterile manufacturing. Expansion of biopharmaceutical facilities and clinical production sites enhances water treatment system installation. Increasing collaboration between domestic and multinational firms accelerates adoption of high-performance purification technologies.
Italy
Italy held a 14% share in 2024, supported by its rising production of generic drugs and sterile formulations. The pharmaceutical sector’s modernization initiatives create strong demand for high-purity water systems. It has shown steady adoption of distillation and reverse osmosis solutions to meet EMA quality benchmarks. The country’s investments in manufacturing expansion and export-oriented drug production encourage water infrastructure growth. Ongoing upgrades to meet EU GMP standards strengthen market penetration among regional producers.
Spain
Spain represented a 12% share in 2024, backed by its growing pharmaceutical exports and manufacturing base. The focus on biosimilars, vaccines, and R&D activities promotes adoption of validated water treatment systems. It benefits from national initiatives supporting technological innovation in pharmaceutical production. Continuous development of modular purification systems supports cost efficiency and process flexibility. Collaborations with global technology providers further improve reliability and system integration.
Rest of Europe
The Rest of Europe region accounted for a 12% share in 2024, encompassing emerging markets such as Russia, Poland, and the Netherlands. Expanding pharmaceutical manufacturing capacity and favorable regulatory reforms support regional growth. Governments promote investments in GMP-compliant infrastructure and water treatment upgrades. Adoption of advanced RO and UV disinfection technologies continues to rise across these markets. It benefits from growing demand for contract manufacturing and rising export potential within Eastern and Northern Europe.
Market Segmentations:
By Type of Pharmaceutical Water
Water for Injection (WFI)
Purified Water
Highly Purified Water
Sterile Water for Injection, Irrigation, and Inhalation
Other
By Treatment Technology
Reverse Osmosis (RO)
Ultraviolet (UV) Disinfection
Distillation
Deionization
Others
By Application
Pharmaceutical & Biotechnology Manufacturing
Research Laboratories & Academic Institutes
Contract Manufacturing Organizations (CMOs)
Others
By Region
United Kingdom (UK)
France
Germany
Italy
Spain
Russia
Rest of Europe
Competitive Landscape
The Europe Pharmaceutical Water Market is highly competitive, driven by technological innovation, strict regulatory standards, and expanding pharmaceutical manufacturing. Leading companies such as Ecolab Inc., Veolia Water Technologies, Thermo Fisher Scientific Inc., Danaher Corporation, and B. Braun Medical Inc. dominate through comprehensive purification portfolios and validated GMP-compliant systems. These firms focus on automation, membrane innovation, and real-time water quality monitoring to maintain compliance and operational efficiency. Mid-tier players like SteriCare Solutions, Baldwin Technology Company, and Sigma-Aldrich (Merck KGaA) strengthen regional presence through customized solutions for research and production facilities. Strategic partnerships, R&D collaborations, and sustainability-focused upgrades enhance market competitiveness. The ongoing transition toward digital monitoring and modular purification systems encourages both established and emerging suppliers to differentiate through energy-efficient and scalable water treatment technologies that meet evolving European Pharmacopeia and EMA requirements.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In December 2024, Veolia Water Technologies launched mobile water services to support pharmaceutical and life science companies across Europe.
In September 2025, LuminUltra completed the acquisition of French microbial-testing firm GL Biocontrol, strengthening its position in Europe’s pharmaceutical and industrial water diagnostics market.
In October 2025, Nijhuis Saur Industries (NSI) acquired Grünbeck Waterbehandeling, a Dutch water treatment firm specialising in industrial process water.
In November 2023, BW Water completed an asset acquisition of H+E Pharma GmbH and S-Tec GmbH in Germany, strengthening its pharma water treatment capabilities.
Report Coverage
The research report offers an in-depth analysis based on Type of Pharmaceutical Water, Treatment Technology, Application and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Demand for high-purity water systems will rise with growing biologics and vaccine production
Automation and digital monitoring will become standard in new water treatment installations.
Pharmaceutical companies will invest more in sustainable and energy-efficient purification systems.
Expansion of contract manufacturing organizations will drive continuous system upgrades.
Regulatory alignment with evolving EMA and GMP standards will shape equipment design.
Adoption of modular and hybrid purification technologies will improve operational flexibility.
Increased focus on validation and quality assurance will strengthen supplier partnerships.
Emerging European markets will witness higher adoption of advanced water purification systems.
Strategic collaborations between global and regional technology providers will accelerate innovation.
Continuous R&D in filtration and distillation technologies will enhance reliability and water purity standards.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: PHARMACEUTICAL WATER MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by Product CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Type of Pharmaceutical Water & Application Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Europe Pharmaceutical Water Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Europe Pharmaceutical Water Export Revenue By Region CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Europe Pharmaceutical Water: Company Market Share
7.2. Europe Pharmaceutical Water Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: PHARMACEUTICAL WATER MARKET – BY TYPE OF PHARMACEUTICAL WATER SEGMENT ANALYSIS
8.1. Pharmaceutical Water Overview by Type of Pharmaceutical Water Segment
8.1.1. Pharmaceutical Water Revenue Share By Type of Pharmaceutical Water
8.2. Water for Injection (WFI)
8.3. Purified Water
8.4. Highly Purified Water
8.5. Sterile Water for Injection, Irrigation, Inhalation
8.6. Others CHAPTER NO. 9: PHARMACEUTICAL WATER MARKET – BY TREATMENT TECHNOLOGY SEGMENT ANALYSIS
9.1. Pharmaceutical Water Overview by Treatment Technology Segment
9.1.1. Pharmaceutical Water Revenue Share By Treatment Technology
9.2. Reverse Osmosis (RO)
9.3. Ultraviolet (UV) Disinfection
9.4. Distillation
9.5. Deionization
9.6. Others CHAPTER NO. 10: PHARMACEUTICAL WATER MARKET – BY APPLICATION SEGMENT ANALYSIS
10.1. Pharmaceutical Water Overview by Application Segment
10.1.1. Pharmaceutical Water Revenue Share By Application
10.2. Pharmaceutical & Biotechnology Manufacturing
10.3. Research Laboratories & Academic Institutes
10.4. Contract Manufacturing Organizations (CMOs)
10.5. Others CHAPTER NO. 11: PHARMACEUTICAL WATER MARKET – REGIONAL ANALYSIS
11.1. Pharmaceutical Water Overview by Region Segment
11.1.1. Europe Pharmaceutical Water Revenue Share By Region
11.1.2. Region
11.1.3. Europe Pharmaceutical Water Revenue By Region
11.1.4. Type of Pharmaceutical Water
11.1.5. Europe Pharmaceutical Water Revenue By Type of Pharmaceutical Water
11.1.6. Treatment Technology
11.1.7. Europe Pharmaceutical Water Revenue By Treatment Technology
11.1.8. Application
11.1.9. Europe Pharmaceutical Water Revenue By Application CHAPTER NO. 12: EUROPE PHARMACEUTICAL WATER MARKET – COUNTRY ANALYSIS
12.1. Europe Pharmaceutical Water Overview by Country Segment
12.1.1. Europe Pharmaceutical Water Revenue Share By Region
12.2. Europe
12.2.1. Europe Pharmaceutical Water Revenue By Country
12.2.2. Type of Pharmaceutical Water
12.2.3. Europe Pharmaceutical Water Revenue By Type of Pharmaceutical Water
12.2.4. Treatment Technology
12.2.5. Europe Pharmaceutical Water Revenue By Treatment Technology
12.2.6. Application
12.2.7. Europe Pharmaceutical Water Revenue By Application
12.3. UK
12.4. France
12.5. Germany
12.6. Italy
12.7. Spain
12.8. Russia
12.9. Rest of Europe CHAPTER NO. 13: COMPANY PROFILES
13.1. Ecolab Inc.
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Financial Overview
13.1.4. Recent Developments
13.1.5. Growth Strategy
13.1.6. SWOT Analysis
13.2. Veolia Water Technologies
13.3. Thermo Fisher Scientific Inc.
13.4. Danaher Corporation
13.5. B. Braun Medical Inc.
13.6. Merck KGaA
13.7. SteriCare Solutions
13.8. Baldwin Technology Company
13.9. Sigma-Aldrich (Merck KGaA)
13.10. Corning Incorporated
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for Europe Pharmaceutical Water Market, and what is its projected size in 2032?
The Europe Pharmaceutical Water Market reached USD 7,235.40 million in 2024 and is projected to achieve USD 14,105.75 million by 2032, reflecting sustained growth.
At what Compound Annual Growth Rate is the Europe Pharmaceutical Water Market projected to grow between 2025 and 2032?
The Europe Pharmaceutical Water Market is projected to expand at a steady CAGR of 8.0% from 2025 to 2032, driven by industrial modernization and biopharma growth.
Which Europe Pharmaceutical Water Market segment held the largest share in 2024?
Water for Injection (WFI) held the largest segment share of 42% in 2024, supported by stringent EMA standards and increased sterile drug production.
What are the primary factors fueling the growth of the Europe Pharmaceutical Water Market?
Growth is fueled by rising biologics production, strict GMP compliance, sustainable purification investments, digital automation adoption, and continuous pharmaceutical infrastructure expansion across key countries.
Who are the leading companies in the Europe Pharmaceutical Water Market?
Key players include Ecolab Inc., Veolia Water Technologies, Thermo Fisher Scientific Inc., Danaher Corporation, B. Braun Medical Inc., Merck KGaA, and Corning Incorporated.
Which region commanded the largest share of the Europe Pharmaceutical Water Market in 2024?
The United Kingdom commanded the largest regional share of 24% in 2024, driven by strong pharmaceutical manufacturing capacity and advanced regulatory-compliant water systems.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Australia Pharmaceutical Water Market size was valued at USD 389.54 million in 2018, grew to USD 779.59 million in 2024, and is anticipated to reach USD 1,736.49 million by 2032, expanding at a CAGR of 9.81% during the forecast period.
The North America Pharmaceutical Water Market was valued at USD 9,849.30 million in 2018, grew to USD 17,393.16 million in 2024, and is projected to reach USD 37,427.29 million by 2032, expanding at a CAGR of 9.4% during the forecast period.
Global Pharmaceutical Water Market size was valued at USD 23,162.04 million in 2018, grew to USD 41,343.44 million in 2024, and is anticipated to reach USD 88,711.39 million by 2032, expanding at a CAGR of 9.33% during the forecast period.
Japan Pharmaceutical Water Market size was valued at USD 819.04 million in 2018, grew to USD 1,672.74 million in 2024, and is anticipated to reach USD 3,843.83 million by 2032, expanding at a CAGR of 10.21% during the forecast period.
The UK Pharmaceutical Water Market was valued at USD 299.29 million in 2018, increased to USD 550.93 million in 2024, and is projected to reach USD 1,087.93 million by 2032, expanding at a CAGR of 8.27% during the forecast period.
The U.S. Pharmaceutical Water Market was valued at USD 5,673.65 million in 2018, increased to USD 11,018.40 million in 2024, and is projected to reach USD 23,471.03 million by 2032, expanding at a CAGR of 9.23% during the forecast period.
The Italy Pharmaceutical Water Market was valued at USD 460.92 million in 2018, grew to USD 817.32 million in 2024, and is projected to reach USD 1,534.50 million by 2032, expanding at a CAGR of 7.63% during the forecast period.
Germany Pharmaceutical Water Market size was valued at USD 658.32 million in 2018 to USD 1,223.46 million in 2024 and is anticipated to reach USD 2,448.13 million by 2032, at a CAGR of 8.44 % during the forecast period.
The France Pharmaceutical Water Market was valued at USD 728.61 million in 2018, grew to USD 1,310.01 million in 2024, and is projected to reach USD 2,505.44 million by 2032, expanding at a CAGR of 7.86% during the forecast period.
The Fabry Disease Therapeutic Market has witnessed steady growth in recent years and is expected to grow at a CAGR of 8.80% between 2024 and 2032. The market was valued at USD 1725.8 million in 2023 and is expected to reach USD 3686.8 million in 2032.
The Foot and Mouth Disease (FMD) Vaccines market size was valued at USD 2.68 billion in 2024 and is projected to reach USD 4.78 billion by 2032, growing at a CAGR of 7.5% during the forecast period.
The Idiopathic Pulmonary Fibrosis (IPF) Treatment market was valued at USD 3.25 billion in 2024 and is projected to reach USD 5.66 billion by 2032, expanding at a CAGR of 7.2% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
